Mérieux Equity Partners
Portfolio
| Company | Sector | Stage | Country |
|---|---|---|---|
| AcuSurgical | Medtech | Series A | |
| Advencis | Biotech, Medtech | ||
| Amplitude Systèmes | Biotech, Medtech | ||
| Amyl Therapeutics | Biotech | Series A | |
| Biobest | Healthtech | ||
| Broken String Biosciences | Biotech | Series A | |
| CEVA Santé Animale | Agritech | France | |
| Cairdac | Medtech | Series A | |
| Cell-Easy | Biotech | Series A | |
| Corflow | Medtech | ||
| Curea Medical GmbH | Medtech | ||
| DOC Generici | Biotech | ||
| Deepull | Medtech | Series B | |
| Dental Monitoring | Healthtech | France | |
| Domus VI | Healthtech | France | |
| Elsan | Healthtech | ||
| GTP Bioways | Biotech | ||
| Health in Code | Biotech, Medtech | ||
| InnoSyn | Biotech | ||
| Inscripta | Biotech | Series E | United States |
| Ivantis | Medtech | United States | |
| Janvier Labs | Biotech | ||
| Kalila Medical | Biotech | United States | |
| KeepMED | Medtech | Series C | |
| Keranova | Medtech | Series B | |
| LNA Santé | Healthtech | France | |
| LabQuality | Biotech | ||
| Laboratoires INELDEA | Healthtech | ||
| Lavorel Medicare | Healthtech | ||
| MRM Health | Biotech | Series B | |
| Mablink Bioscience | Biotech | Series A | France |
| Mabtech | Biotech, Medtech | ||
| Mimetas | Biotech | Series B | |
| Neurinnov | Medtech | Seed | |
| Nutragroup | Healthtech | ||
| Ona Therapeutics | Biotech | Series B | |
| Origene | Biotech, Medtech | United States | |
| Physioassist | Medtech | Series B | |
| Piercan | Biotech | France | |
| Plantex | Healthtech | ||
| Prodigest | Biotech | Series A | |
| Prothea Technologies | Biotech, Medtech | ||
| Quantalife | Biotech | ||
| SERB Pharmaceuticals | Biotech | ||
| SGH Medical Pharma | Biotech, Medtech | ||
| SWIXX BioPharma | Biotech | ||
| SeqOne Genomics | Healthtech, Medtech, Biotech | Series A | France |
| Seqens | Biotech | ||
| Supersonic Imagine | Medtech, Biotech | France | |
| TARA Biosystems | Biotech | Series A | United States |
| TWIST Bioscience | Biotech | United States | |
| Theravia | Biotech | ||
| Triple Ring Technologies | Biotech | United States | |
| XERIS Pharmaceuticals | Biotech | IPO | United States |
Recorded changes
- 20 June 2026 Deepull's stage changed from Seed to Series B (Mérieux Equity Partners)
Spotted something wrong? Tell us.